How Cellectis’ UCART Gene-Edited CAR‑T Therapy Is Redefining Cancer Treatment
Explore Cellectis, the Paris‑based biopharma innovator crafting gene‑edited UCART CAR‑T therapies that redefine precision oncology. Discover their market outlook and R&D focus.
2 minutes to read
